SELECTA BIOSCIENCES INC (SELB)
US8162121045 - Common Stock
Overall SELB gets a fundamental rating of 2 out of 10. We evaluated SELB against 588 industry peers in the Biotechnology industry. SELB has a bad profitability rating. Also its financial health evaluation is rather negative. SELB is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year SELB has reported negative net income.
In the past year SELB has reported a negative cash flow from operations.
In the past 5 years SELB reported 4 times negative net income.
SELB had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
SELB has a better Return On Assets (-25.12%) than 77.33% of its industry peers.
Looking at the Return On Equity, with a value of -53.55%, SELB is in the better half of the industry, outperforming 63.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.12% | ||
| ROE | -53.55% | ||
| ROIC | N/A |
ROA(3y)-12.13%
ROA(5y)-47.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for SELB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SELB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SELB has been increased compared to 1 year ago.
SELB has more shares outstanding than it did 5 years ago.
SELB has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -3.16, we must say that SELB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.16, SELB is in line with its industry, outperforming 44.33% of the companies in the same industry.
A Debt/Equity ratio of 0.21 indicates that SELB is not too dependend on debt financing.
SELB's Debt to Equity ratio of 0.21 is on the low side compared to the rest of the industry. SELB is outperformed by 69.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.16 |
ROIC/WACCN/A
WACC11.18%
2.3 Liquidity
SELB has a Current Ratio of 4.18. This indicates that SELB is financially healthy and has no problem in meeting its short term obligations.
SELB has a Current ratio (4.18) which is comparable to the rest of the industry.
SELB has a Quick Ratio of 4.18. This indicates that SELB is financially healthy and has no problem in meeting its short term obligations.
SELB has a Quick ratio (4.18) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.18 | ||
| Quick Ratio | 4.18 |
3. Growth
3.1 Past
SELB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -237.50%.
Looking at the last year, SELB shows a very negative growth in Revenue. The Revenue has decreased by -61.85% in the last year.
Measured over the past years, SELB shows a very strong growth in Revenue. The Revenue has been growing by 250.30% on average per year.
EPS 1Y (TTM)-237.5%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-216.67%
Revenue 1Y (TTM)-61.85%
Revenue growth 3Y155.01%
Revenue growth 5Y250.3%
Revenue growth Q2Q-86.63%
3.2 Future
The Earnings Per Share is expected to decrease by -28.87% on average over the next years. This is quite bad
SELB is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -11.85% yearly.
EPS Next Y-228.11%
EPS Next 2Y-62.59%
EPS Next 3Y-34.35%
EPS Next 5Y-28.87%
Revenue Next Year-72.53%
Revenue Next 2Y-37.57%
Revenue Next 3Y-26.62%
Revenue Next 5Y-11.85%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SELB. In the last year negative earnings were reported.
Also next year SELB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SELB's earnings are expected to decrease with -34.35% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-62.59%
EPS Next 3Y-34.35%
5. Dividend
5.1 Amount
SELB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SELECTA BIOSCIENCES INC
NASDAQ:SELB (11/13/2023, 7:15:05 PM)
After market: 0.9 +0.02 (+2.13%)0.8812
-0.08 (-8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap135.20M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.12% | ||
| ROE | -53.55% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.18 | ||
| Quick Ratio | 4.18 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-237.5%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-228.11%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-61.85%
Revenue growth 3Y155.01%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y